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Aims and Scope.AimsofthepaperaretosuggestthebesttreatmenttoimprovetheglycemiccontrolinpatientswithType2diabetes
usinghypoglycemicagents,inparticularly,wethinkthateverypatientisdiﬀerentfromanotheroneintermsofBMI,familyhistory,
durationofthediseaseandsoon.Weproposeforeveryclinicalaspectthebesthypoglycemicagentstouse,consideringthescientiﬁc
evidence and physiopathology.
1.Introduction
In recent years, a series of innovative molecules have been
introduced to treat type 2 diabetes, a challenging task as the
disease is complex and multifactorial, due to defects in insu-
lin secretion and action, laden with a heavy impact on public
health because of its growing prevalence.
A good glycemic control, the best guarantee to reduce
the risk of development and/or progression of microvascular
disease, remains the cornerstone of diabetes management,
although its impact on macrovascular disease is still under
debate. However, any strategy for glycemic control should be
integratedinacontextofmultifactorialinterventions tocon-
trol all cardiovascular risk factors associated with diabetes.
In the 1990s, a patient with newly diagnosed diabetes,
with a glycated hemoglobin (A1c)o f7 . 5 % ,s y s t o l i cb l o o d
pressure of 140 mmHg and LDL-cholesterol of 130mg/dL,
would have been given the recommendation to reduce body
weight and to increase physical activity. Nowadays, the same
patient, in addition to life style changes, would start an in-
tensive pharmacological treatment.
As reported by the UKPDS [1], intensive therapy, when
compared to the conventional form, signiﬁcantly reduced
the relative risk of myocardial infarction and death from
any cause. In contrast, recent clinical studies (ACCORD,
ADVANCE, and VADT) [2–4] yielded surprising results:
intensive care, even when lowering A1c below 7%, was not
associated with any signiﬁcant reduction in cardiovascular
(CV) mortality. Why such contradictory results? To answer
this question we must analyze the diabetic patients enrolled
in the above-mentioned trials: newly diagnosed patients
with no prior CV event in the UKPDS, patients with long-
standing disease and a high prevalence of micro- and ma-
crovascular complication in the ACCORD, ADVANCE, and
VADT trials. In a recent metaregression analysis, in addition
tothedurationofdisease,higherbodymassindex(BMI)and
severe hypoglycemia were found associated with a greater
risk of CV events in patients undergoing intensive therapy
[5].
Altogether, these data suggest that several factors can be
taken into consideration when planning treatment of diabe-
tes, including duration and stage of disease, life expectancy,
risk of hypoglycemia, and risk factors for CV disease (CVD).
Consequently, we must consider not only the type of phar-
macological agents used to control glucose, but also the phe-
notype of the diabetic patient when planning modern treat-
ment.
Of importance to lifestyle changes and weight control, it
is necessary to know the mechanism of action of all hypogly-
cemic agents, each endowed with speciﬁc properties. They
are diﬀerent from each other and should be appropriately
rather than haphazardly used. The goal of treatment is not2 ISRN Endocrinology
the mere reduction of hyperglycemia, possibly with each
individual hypoglycemic agent, but rather to reach the best
glycometabolic control while preserving β-cell function and
quality of life.
The guidelines, proposed by the American Diabetes As-
sociation (ADA) and the European Association for the Study
of Diabetes (EASD), provide a series of steps, the ﬁrst of
which is the use of metformin. The subsequent steps involve
the progressive addition of all other hypoglycemic agents,
including insulin [6].
In this article, we shall discuss when and how to use
each individual hypoglycemic agent. With the exclusion of
acarbose, these can be divided into two groups: those that
increase the patient’s secretion of insulin (sulphonylureas,
glinides and incretins) and those that enhance its effective-
ness (metformin and pioglitazone). The fact that hypoglyce-
mic agents substantially have the same eﬀect on A1c does not
justify their uncritical use. Their choice is not at all optional
but should depend on the properties of the drug and the
clinical evidence yielded by persuasive studies.
Subsequently, we shall discuss the use of these drugs in
a particular group of diabetic patients, those with newly
diagnosed type 2 diabetes: how should we treat them? Which
drugs should we use?
2. When and How Should WeUse Metformin?
Metformin is the only biguanide presently available almost
everywhere.Itactsmainlyontheliver,whereitdecreasesglu-
coseproduction,thusloweringfastingplasmaglucose(FPG).
Itmayimproveperipheralglucosedisposalwhilesuppressing
hunger and promoting weight reduction. Since it does not
increase insulin levels, although it requires the presence of
endogenous insulin, metformin can also be used in patients
with type 1 diabetes, when they have residual functioning
pancreatic β-cells. Generally, it is well tolerated, the most
common adverse eﬀects being gastrointestinal. When appro-
priately used, the risk of lactic acidosis is minimal [7]. The
UKPDS demonstrated the beneﬁt of metformin therapy on
CV outcomes, especially in overweight-obese patients [1].
Thesedatahingeonthefactthatmetforminisconsidered
“ﬁrst line” oral therapy in type 2 diabetes, especially in over-
weight patients. An additional indication is its low cost and
the fact that it can be associated with every other glucose-
lowering agent, including insulin.
Metformin should be taken with, or immediately after, a
meal. To avoid its common gastrointestinal eﬀect, it should
be introduced using initial low doses, gradually titrated up-
ward. People should be informed that these adverse eﬀects
often improve after a few days of continued treatment. Met-
formin should be discontinued during severe illnesses like
myocardial infarction, pneumonia, severe infection, and/or
dehydration, as it may aggravate tissue hypoxia and accumu-
late when renal function is impaired. It may be appropriate,
in these cases, to use other glucose-lowering agents, includ-
ing insulin. It is a good rule, given the increasingly wide
use of iodine contrast agents even when serum creatinine is
increased, to discontinue metformin prior to these radio-
graphic procedures.
3. When andHow Should We Use
Sulphonylureas/Glinides?
Sulphonylureas increase the release of endogenous insulin
from β-cell. They exert eﬀects on A1c similar to those of met-
formin, but their use entails a greater risk of hypoglycemia
and of undesired weight gain. Even though this risk is lower
with the newer sulphonylureas (glipizide, glimepiride) [8],
these episodes, more frequent and dangerous in the elderly,
severelylimittheiruse.Inaddition, anunwantedweightgain
of approximately 2kg is common after introducing sulpho-
nylureas.
Old age, renal impairment, and liver disease are condi-
tions where sulphonylureas should not be used.
In patients suﬀering from inadequate glycemic control,
sulphonylureas can achieve signiﬁcant improvements when
added to metformin [9]. Another controversial aspect of sul-
phonylureastreatmentistheirCVsafety.Incomparisonwith
metformin, sulphonylureas treatment seems associated with
a signiﬁcant increase in adverse CV outcomes [1, 10, 11]. Al-
though still under debate, this issue must be kept in mind
when planning long-term treatment.
Like sulphonylureas, glinides stimulate insulin secretion.
Their shorter half-life requires a more frequent administra-
tion. Like sulphonylureas, glinides cause a similar weight
gain, although hypoglycemia seems less frequent [12].
Even though sulphonylureas are the most widely used
oral antidiabetic agents, in the future they will be used more
sparingly. In our opinion, this scenario is inevitable, con-
sidering the pathophysiology of type 2 diabetes. Patients
with type 2 diabetes very often have lost 50% of their β-cell
functionatthe time ofdiagnosis [13].Consequently, sulpho-
nylureas, while causing a deceptive improvement of A1c,d o
in fact accelerate β-cell dysfunction by imposing an addi-
tional burden on residual β-cells secretion. The clinical cor-
relate of this phenomenon is known as “secondary failure”
and it represents the inevitable fate of all oral hypoglycemic
agent, especially sulphonylureas. We believe that the less
we use of sulphonylureas, the less will be the relevance of
this “secondary failure.” Given that β-cell dysfunction is
prominent at the time of diagnosis of diabetes and given the
rate of decline of β-cell function with time [10, 13], it does
not seem necessary to trigger the production of endogenous
insulin by a dysfunctional β-cell, when the plasma levels of
insulin itself are already, in almost all instances, elevated.
Given this evidence, drugs enhancing the eﬃcacy of insulin
would appear more appropriate.
In our opinion, because of the aforementioned consider-
ations, sulphonylureas should no longer be used.
4. When andHow Should We Use
α-GlucosidaseInhibitors?
Theinhibitionofintestinalα-glucosidaseinthebrushborder
of the small intestine delays the absorption and digestion
of complex carbohydrates. Although these agents do not
increase the response to insulin of peripheral tissues, their
ability to curb the rise in plasma glucose after meals canISRN Endocrinology 3
reduce plasma insulin levels and the need to administer insu-
lin.Aspredictedbytheirmechanismofaction,hypoglycemic
adverse eﬀects and weight gain do not occur [14]. There are
no data on long-term eﬀects of α-glucosidase inhibitors in
terms of mortality, morbidity, and quality of life. However,
we believe that the signiﬁcant eﬀect in preventing the con-
version to type 2 diabetes in patients with impaired glucose
tolerance (IGT) exerted by acarbose, the α-glucosidase in-
hibitor most widely used, compared with placebo [15], high-
lights the possible clinical beneﬁts of acarbose. While these
beneﬁts are not established yet, they will be in all likelihood
demonstrated in the near future.
The patients best suited for α-glucosidase inhibitor treat-
ment are those with high or excessive postprandial glucose
levels. This speciﬁcity expands their use to all patients, in-
cluding type 1 diabetes.
These agents are quite safe, but they often cause dose
related gastrointestinal adverse eﬀects like disturbing bloat-
ing,ﬂatulenceanddiarrhea.Thesesymptoms,theprevalence
of which is similar to that observed with metformin [16],
mainly arise from the fermentation of undigested carbohy-
drates by colonic bacteria.
Theα-glucosidaseinhibitorsshouldbeintroducedinlow
doses, with a gradual step-wise escalation. Some patients do
not tolerate the higher doses, in which case dose reduction is
appropriate.
We believe that α-glucosidase inhibitors, if tolerated, can
be used alone or in combination with other agents for treat-
ing all patients with type 2 diabetes.
5. When and How Should We Use
Thiazolidinediones?
Thiazolidinediones increase whole-body insulin sensitivity
by activating nuclear receptors. Presently, only pioglitazone
is available for patients’ use. In this report, we shall not
mention rosiglitazone, which is not licensed for use yet, and
in few countries it has recently been taken oﬀ the market
because of undesired CV side-eﬀects.
The availability of an oral drug that can eﬀectively coun-
ter insulin resistance, a crucial pathophysiological compo-
nent of diabetes [17], has expanded our treatment options.
However, it is essential to use the drug properly and the
physicians who really know its properties will not resort to
its unselected use.
Pioglitazone is eﬀective in lowering A1c when used alone
as well as in combination with metformin, sulfonylurea or
insulin [18]. Weight gain, ﬂuid retention, and risk of frac-
tures (only in women) are its main side eﬀects [16, 19]. It
seems that fat accumulation is largely subcutaneous, with
redistribution of fat from visceral deposits, while ﬂuid reten-
tion usually appears as peripheral edema, with a consequent
risk of new or worsening congestive heart failure (CHF) in
predisposed individuals [6].
After the evidence reporting the unwanted side eﬀects of
the other thiazolidinediones, the CV safety of pioglitazone
is currently under debate. A Cochrane systematic review
reported insuﬃcient evidence to draw conclusions on CV
and non-CV outcomes [20].
Substantially pioglitazone, compared with treatments
basedondiﬀerentdrugs,signiﬁcantlyreducedcompositeCV
outcomes [21, 22], even when used in diabetic patients with
a long disease duration and previous myocardial infarction
or stroke [18]. On the other hand, the higher risk of CHF re-
ported should not be disregarded [21, 23].
In our opinion, pioglitazone is an important option for
diabetes treatment. There is concern stemming from the fact
that the drug acts on nuclear receptors of all cells, raising
questions on its possible long-term eﬀects. Recently, an in-
creased incidence of bladder cancer attributed to pioglita-
zone use has been reported [24]. However, the beneﬁts of
pioglitazonemayoutweightheassociatedrisks.Onlypatients
with marked insulin resistance should be selected to receive
the drug. We believe that the association of pioglitazone
with metformin is very advantageous and that it should be
encouraged also for the beneﬁcial eﬀects on the atherogenic
lipid proﬁle induced by pioglitazone itself [25]. When ankle
edema occurs, it is usually appropriate to discontinue the
drug.
Pioglitazone use has been recently extended to nonal-
coholic fatty liver disease and prediabetes [26, 27]. It is a
drug with an important clinical potential, its strength being
its attractive mechanism of action in countering insulin
resistance.
6. When andHow Should We Use Incretins?
The observation that insulin is released more eﬃciently after
an oral glucose load than with an intravenous injection is
known as the incretin eﬀect[28]. This eﬀect, occurring when
intestinally derived peptides, as the glucagon-like polypep-
tide 1 (GLP-1), stimulates insulin release in response to oral
glucose and is rapidly lowered by the enzymatic digestion of
the peptides operated by glycoprotein dipeptidyl peptidase
(DPP-4). The incretins work by enhancing the sensitivity of
β-cell to glucose, which causes enhanced glucose-dependent
insulin release. Substantially, they exert an insulinotropic ac-
tion secondary to a marked suppression of α-cells; thus, they
protect the β-cell from an unfavorable environment where
glucagon is prominent [29], making available the function-
ing of β-cell that was hampered by α-cell overactivity.
It is possible to enhance the incretin pathway in two
ways: by slowing the peptide breakdown through inhibition
of DPP-4 release, or by enhancing the action of GLP-1 itself.
The DPP-4 inhibitors, now available in clinical practice,
prolong the action of endogenous GLP-1. These oral drugs,
similarly to other hypoglycemic agents, were shown to be ef-
fective in lowering A1c,[ 30] .T h e ya r ew e l lt o l e r a t e d ,w e i g h t
neutral, and they do not induce hypoglycemia [31].
GLP-1 mimetics, administered only subcutaneously, are
resistant to the breakdown by the DPP-4 enzyme, resulting
in more prolonged action. They exert systemic actions com-
pared to DPP-4. In addition to the insulinotropic action in
responsetoingestedglucoseandtotheinhibitionofinappro-
priateglucagonsecretion,theydelaygastricemptying,result-
ing in slower absorption of glucose following meals, while
promoting satiety attended by signiﬁcant weight reduction
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The current available GLP-1 mimetics are exenatide,
whichhasahalf-lifeoffourhoursrequiringatwicedailysub-
cutaneous injection, and liraglutide, which has a half-life of
approximately 12 hours, requiring once daily subcutaneous
injection.ThereductionofA1c iswelldocumented,similarto
that aﬀorded by insulin [31] and more important than that
obtained with other glucose-lowering agents [31, 32].
Both exenatide and liraglutide are generally well tolerat-
ed, while severe hypoglycemia is rare. The most common ad-
verse events are gastrointestinal, especially nausea. Data pur-
porting to show an increase incidence of acute pancreatitis
in patients treated with incretins is considered inconclusive
[31, 32].
Our opinion is that a large proportion of people with
type 2 diabetes can experience an important advantage from
incretin therapy. The beneﬁcial action on glucagon metab-
olism implemented by incretin is unique. It would not be
wise to disregard this advantage, since in diabetes increased
glucagon levels are invariably present and constitute an im-
portantpathophysiologiccomponentofthedisease.Actually,
incretins may be used to improve glycemic control in obese
adults for whom weight loss is a priority, although we believe
that these drugs will be more eﬀective if used early in the
course of the disease, when the β-cell can still regain part of
its function.
7. Pharmacological Management of
IndividualsNewly Diagnosedwith
Type2Diabetes
Mostdiabeticpatientsareidentiﬁedlaterinthecourseofdis-
ease, when the FPG is much higher than 140mg/dL, and A1c
concentration is well above 7–7.5%.
This clinical situation is not ideal for two relevant rea-
sons.
The ﬁrst one is the clinical inertia. This, representing the
failure to initiate or advance therapy in a patient who is not
at the evidence-based therapeutic goal, is now considered a
primary reason for poor metabolic control [33]. The causes
of clinical inertia identiﬁed are multifactorial, including the
attitude of physicians, organizational aspects, and compli-
ance of patients. The strongest barriers raised against a
more advanced therapeutic intervention or intensiﬁcation
treatment are the risk of hypoglycemia and of weight gain.
Therefore, we believe that the early use of the new glucose-
lowering agents, like incretins, can minimize these risks with
a positive impact on disease progression and a delay in the
need of insulin administration.
The second reason is that most patients with type 2
diabetes, as well demonstrated in UKPDS [10], have already
lost 50% of their β-cell function at the time of diagnosis,
underscoring the important role of β-cell dysfunction, in
addition to that of insulin resistance. In the same study,
there was evidence of a relentless progressive loss of β-cell
function over the ensuing years, associated with glycemic
deterioration, which occurred regardless of treatment. At
the time of patient enrollment, beside life style intervention,
only insulin, sulphonylureas, and metformin were used. We
do not know whether the use of pioglitazone and incretins
could have better preserved β-cell function. As previously
discussed, both pioglitazone and incretins seem to be able
to spare secretion. In fact, pioglitazone can slow down the
progressiontotype2diabeteswhenusedinIGTpatient[27],
whilebothGLP-1mimeticsandDPP-4inhibitorsimproveβ-
cell function measured by HOMA-β [30].
These data, taken together, suggest that, if it is true that
the earlier the treatment is begun the better is its outcome,
it is also true that the earlier we diagnose diabetes, the more
eﬀectively we can control it.
Recently, the ADDITION-Europe study compared in-
tensive multifactorial therapy with routine care in type 2
diabetic patients detected by screening [34]. Unlike other
clinical trials, as ACCORD, ADVANCE, and VADT [2–4],
the ADDITION-Europe study enrolled diabetic patients
whose diagnosis had been reached by a programmed screen-
ing design. Although only a small trend towards CV beneﬁt
(−17%) was recorded from intensive treatment compared
with routine care, this study conveys an important message.
In ACCORD, ADVANCE, and VADT trials, where the dia-
betic patients had a long duration of disease and/or previous
CV events, the intensive multifactorial therapy, compared
with the conventional one, was associated to a significantly
increased incidence of CV events. This suggests that any
treatment is more eﬀective when started early. In the case
of diabetes, any treatment introduced earlier than the time
of routine diagnosis will turn out to be advantageous. For
example, the screening of diabetes by the oral glucose tol-
erance test (OGTT) can also dictate the choice of a speciﬁc
drug.Werecentlyreportedevidenceofaheterogeneouspres-
entation of type 2 diabetes diagnosed by the OGTT [35].
Based on the OGTT, 103 subjects out of 1277 (8.1%) were
found aﬀected by new onset type 2 diabetes. On the basis of
theglucosecut-oﬀvaluesfordiagnosingtype2diabetes,FPG
> 125 and/or 2 hour plasma glucose (2hPG) ≥ 200mg/dL,
three diﬀerent disease presentations are possible. In fact, out
of 103 newly diagnosed type 2 diabetics, 22 were diabetics
only because of their elevated FPG, 55 only because of their
elevated 2hPG, and, ﬁnally, 26 because of both. These results
are consistent with a heterogeneous presentation of type 2
diabetes, detectable before the common routine diagnosis,
thus allowing the possibility of speciﬁc treatments. When
FPG is elevated, probably metformin and pioglitazone are
more suitable [6, 17], while pioglitazone, acarbose, and in-
cretins are more suitable when 2hPG is elevated [15, 17, 30].
8. Conclusion
Type2diabetesisinsigniﬁcantexpansion.Treatmentisoften
conservative andlimited toanunsatisfactorycontrolfocused
mainly on glucose values. The common therapeutic scenario
reliesontheuseofanoralagentfollowedbythestepaddition
of others delaying insulin treatment.
Presently, innovative molecules have been made availa-
ble:physiciansneedtounderstandthemproperly.Westrong-
ly recommend that diabetes be treated as early as possible.
Onlyinthisway,thecatastrophicconsequencesofthedisease
can be eﬀectively prevented and limited.ISRN Endocrinology 5
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